Multi-omic data integration trust: combining genomics, proteomics, and metabolomics

Multi-omic integration is not a data science problem. It is a data trust problem.

Researchers combine genomics, proteomics, and metabolomics because no single omic layer captures biological reality on its own. DNA tells you what could happen. Proteins tell you what is happening. Metabolites tell you what already happened. Together, they create a systems-level view of disease. Separately, each layer carries its own provenance gaps, quality failures, and temporal mismatches.

The current literature on multi-omic integration focuses almost entirely on analytical methods: network-based approaches, Bayesian models, matrix factorization, deep learning architectures. What it ignores is whether the data feeding those methods was ever trustworthy in the first place.

What is multi-omic data integration?

Multi-omic data integration is the computational and statistical process of combining measurements from two or more omic layers to produce a unified biological interpretation. These layers typically include genomics (DNA sequence and variants), transcriptomics (RNA expression), proteomics (protein abundance and modification), metabolomics (small molecule profiles), and epigenomics (DNA methylation, histone modification).

The goal is straightforward: no single molecular layer explains a complex phenotype. Type 2 diabetes involves genetic risk variants, altered gene expression in pancreatic beta cells, disrupted insulin signaling at the protein level, and abnormal lipid and glucose metabolite profiles. A model trained on only one of these layers will miss the others.

Integration methods fall into three broad categories. Early integration concatenates all omic features into a single matrix before analysis. Late integration analyzes each omic layer independently and then combines the results. Intermediate integration uses techniques like multi-kernel learning or network fusion to find shared structure across layers during analysis.

Each approach has tradeoffs. But all three share the same dependency: the data entering the pipeline must be trustworthy across every layer simultaneously.

What is genomics, proteomics, and metabolomics?

Genomics studies the complete set of DNA in an organism, including gene sequences, structural variants, single nucleotide polymorphisms (SNPs), and copy number variations. Whole genome sequencing (WGS) and whole exome sequencing (WES) are the primary technologies. Genomic data is relatively stable over a patient's lifetime, but the provenance chain from sample collection through library preparation, sequencing, alignment, and variant calling introduces multiple points of potential error.

Proteomics measures the full complement of proteins in a biological sample, including post-translational modifications like phosphorylation and glycosylation. Mass spectrometry is the dominant platform, with liquid chromatography-tandem mass spectrometry (LC-MS/MS) being the most common workflow. Proteomic data is highly dynamic. Protein expression changes by tissue, time of day, disease state, and even the interval between sample collection and processing. A plasma sample left at room temperature for two hours will produce a different proteomic profile than one processed immediately.

Metabolomics captures small molecules (metabolites) that are the end products or intermediates of cellular metabolism. These include amino acids, lipids, sugars, and organic acids. Nuclear magnetic resonance (NMR) and mass spectrometry are the primary detection methods. Metabolomic data is the most volatile of the three. A patient's metabolome shifts with their last meal, their medication schedule, their stress level, and their circadian rhythm.

The trust implications are clear. Each layer has a fundamentally different temporal stability profile. Genomic data from 2019 may still be valid. Metabolomic data from last Tuesday may already be stale.

What is a multi-omic approach?

A multi-omic approach is a research or clinical strategy that intentionally collects and analyzes data from multiple molecular layers to build a more complete model of a biological system. Rather than studying a disease through one molecular lens, a multi-omic approach acknowledges that causation flows through multiple layers simultaneously.

In oncology, a multi-omic approach might combine tumor genomics (to identify driver mutations), proteomics (to confirm which mutated genes actually produce altered proteins), and metabolomics (to detect metabolic reprogramming like the Warburg effect). This layered view enables more precise patient stratification and treatment selection than any single assay.

The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) are among the largest multi-omic research programs. TCGA characterized over 20,000 primary cancer samples across 33 cancer types using genomic, epigenomic, and transcriptomic data. CPTAC extended this by adding proteomic and phosphoproteomic characterization.

But scale does not equal trust. A 2023 analysis found that up to 15% of publicly available omic datasets contain batch effects severe enough to confound biological conclusions. When you integrate three datasets that each carry a 15% batch effect risk, the compounded error probability is not 15%. It is significantly higher.

What is multi-omics and proteomics?

Proteomics occupies a unique position in multi-omic integration because it sits between the genome and the phenotype. While genomics tells you what could be expressed, proteomics tells you what is actually expressed, at what abundance, and with which modifications.

This makes proteomics the validation layer for genomic findings. A missense mutation identified by WGS only matters if the gene is expressed and the altered protein is present at functional levels. Proteomics provides that confirmation.

However, proteomic data is also the hardest to standardize across sites. Mass spectrometry platforms vary widely in sensitivity, dynamic range, and reproducibility. A study published in Nature Methods found that the same plasma sample analyzed on different mass spectrometry platforms produced quantitative agreement on only 60-70% of detected proteins. This means that integrating proteomic data from multiple sites without rigorous quality scoring introduces a concordance problem that cascades through every downstream analysis.

Key statistics

DTI dimension weights for health data trust scoring

Multi-omic integration projects are growing rapidly, but trust infrastructure has not kept pace. These numbers frame the scale of the problem.

Up to 15% of publicly available omic datasets contain batch effects severe enough to confound biological conclusions, according to a 2023 systematic review of multi-omic studies.

Cross-platform agreement for proteomic quantitation ranges from only 60-70% for the same sample analyzed on different mass spectrometry instruments.

The Human Protein Atlas estimates that only 44% of all human proteins have been reliably quantified across tissues, meaning proteomic integration relies on incomplete reference maps.

TCGA characterized over 20,000 primary cancer samples across 33 cancer types, but fewer than 3,000 of those samples have matched proteomic data from CPTAC.

SuperTruth's DTI Engine scores data across 8 dimensions with Provenance weighted at 25%, the single highest weight, reflecting the reality that origin and chain of custody determine everything downstream.

The compounding trust problem in multi-omic integration

Multi-omic trust failure: per-layer scoring vs integrated ceiling

When you integrate two or more omic layers, you do not just combine data. You combine trust profiles. And trust does not average. It compounds at the weakest point.

Consider a common integration scenario: a research team combines whole exome sequencing data (collected in 2021, processed through a validated bioinformatics pipeline with full provenance documentation) with metabolomic profiles (collected in 2024, processed through an in-house pipeline with no external validation and no documentation of sample handling times).

The genomic data might score 85 out of 100 on a trust index. The metabolomic data might score 40. When these two layers are integrated, the combined dataset does not score 62.5. It scores closer to 40, because any finding that depends on metabolomic input inherits the metabolomic trust ceiling.

This is the principle that most integration platforms ignore. They focus on statistical harmonization (batch correction, normalization, imputation) without ever asking whether the input data was trustworthy before harmonization began. Correcting for batch effects in data with undocumented provenance is like adjusting the color balance on a photograph that might be of the wrong patient.

Where multi-omic trust breaks down layer by layer

Each omic layer has characteristic failure modes that affect trust differently.

Genomic trust failures tend to be provenance-related. Was the sample from the right patient? Was germline contamination excluded from somatic variant calls? Was the reference genome version documented? These are chain-of-custody problems. Genomic data is relatively stable once generated correctly, but errors in the generation process persist permanently because DNA does not change between measurements.

Proteomic trust failures tend to be quality and concordance problems. Was the sample processed within the required time window? Were the mass spectrometry calibration standards documented? Do protein quantitations agree across replicates? Proteomic data is highly sensitive to pre-analytical variables. A landmark 2019 study showed that plasma protein profiles change measurably within 30 minutes of collection if samples are not processed according to strict protocols.

Metabolomic trust failures tend to be recency and stability problems. Metabolite profiles shift with diet, medication, circadian rhythm, and stress. A fasting metabolomic sample and a postprandial sample from the same patient on the same day can look like they came from different people. If the collection conditions are not rigorously documented and controlled, the data is uninterpretable regardless of the analytical quality.

Why AI models trained on unscored multi-omic data fail

AI models are increasingly applied to multi-omic datasets for tasks like patient stratification, biomarker discovery, drug target identification, and treatment response prediction. These models are powerful pattern detectors. They are also powerful noise amplifiers.

A deep learning model trained on integrated genomic-proteomic data will find correlations. It has no way of knowing whether those correlations reflect biology or reflect correlated batch effects, temporal mismatches, or provenance errors across layers. A model that identifies a genomic-proteomic signature for drug response is useless if the proteomic data was collected under inconsistent conditions across the training cohort.

The FDA's evolving guidance on AI/ML-based medical devices increasingly emphasizes training data quality and provenance. For multi-omic AI models seeking regulatory clearance, the ability to demonstrate trust scoring at the individual record level, across all contributing omic layers, will become a requirement rather than a recommendation.

Scoring multi-omic data before integration

The solution is not better integration algorithms. It is trust scoring before integration begins.

Every omic record entering an integration pipeline needs an independent trust score that accounts for its specific failure modes. Genomic records need provenance-weighted scoring that tracks the sample from collection through variant calling. Proteomic records need quality and concordance-weighted scoring that documents pre-analytical conditions and cross-platform agreement. Metabolomic records need recency and stability-weighted scoring that captures collection conditions and temporal validity.

The DTI framework scores every health data record from 0 to 100 across eight dimensions: Provenance (25%), Consent (20%), Recency (15%), Quality (10%), Concordance (10%), Validation (10%), Breadth (5%), and Stability (5%). For multi-omic data, this framework can be applied independently to each omic layer, producing per-layer trust scores that determine whether integration should proceed at all.

A practical implementation might set a DTI floor of 70 for any omic layer entering an integration pipeline. If genomic data scores 88, proteomic data scores 75, and metabolomic data scores 55, the metabolomic layer is excluded or flagged until its trust score is remediated. This prevents the compounding trust degradation that contaminates the entire integrated dataset.

What this means for research consortia and pharma

Multi-omic studies are expensive. A single multi-omic cancer study with matched genomic, proteomic, and metabolomic profiling can cost $5,000-$15,000 per patient. When 15% of the resulting data carries batch effects severe enough to confound conclusions, the financial waste is staggering.

For pharmaceutical companies using multi-omic data to support drug development programs, the FDA expects documented data provenance for every dataset used in regulatory submissions. Multi-omic integration multiplies the provenance documentation burden by the number of omic layers. Without automated trust scoring, this documentation is manual, incomplete, and audit-vulnerable.

For research consortia like TCGA and CPTAC, the challenge is that contributing sites have different sample handling protocols, different analytical platforms, and different quality assurance standards. Trust scoring at the record level, applied uniformly across contributing sites, creates a common quality currency that makes cross-site integration defensible.

The path forward

Multi-omic integration will define the next decade of precision medicine. The analytical methods are mature. The biological rationale is beyond dispute. The data trust infrastructure is what is missing.

Every multi-omic dataset is only as trustworthy as its weakest omic layer. Every AI model trained on multi-omic data inherits the trust profile of its training data. And every clinical decision informed by multi-omic AI depends on whether anyone scored the data before the model saw it.

The DTI Engine scores every health data record from 0 to 100 across 8 trust dimensions before your AI model sees it. For multi-omic integration projects, this means independent trust scoring of genomic, proteomic, and metabolomic layers with enforced DTI floors that prevent untrustworthy data from contaminating integrated analyses. If your team is evaluating multi-omic data for training, regulatory submission, or clinical use, contact Louis Simeonidis at louis@supertruth.ai or (215) 918-4140.

Further reading:

DTI™ Engine

Research solution

Genomic data trust: provenance requirements for precision medicine

Biobank sample provenance: genetic data trust requirements for research use

Why AI models trained on unscored health data will fail in production